Association Between Depression and Functional Vision Loss in Persons 20 Years of Age or Older in the United States, NHANES 2005-2008

Zhang, Xinzhi; Bullard, Kai McKeever; Cotch, Mary Frances; Wilson, Martin; Rovner, Barry W.; McGwin, Gerald; Owsley, Cynthia; Barker, Lawrence; Crews, John E.; Saaddine, Jinan B.

doi:10.1001/jamaophthalmol.2013.2597

Cited by 212 publications

(184 citation statements)

References 73 publications

(72 reference statements)

Supporting

Mentioning

168

Contrasting

Unclassified

Order By: Relevance

“…Patients in this study were on anti-VEGF therapy and the great majority of them had good visual acuity and did not have visual impairment according to the WHO's criteria (40). We still found that a percentage of wAMD patients are clinically depressed and anxious within the same prevalence range found in previous studies conducted with adults with visual impairment (53)(54)(55). Additionally, we rejected our hypothesis that depression and anxiety are negatively correlated with visual acuity, which is not consistent with some previous literature suggesting that patients with lower visual acuity are more likely to suffer from depression than patients with better visual acuity (29,30).…”

Section: Discussioncontrasting

confidence: 91%

Experience of Anti-VEGF Treatment and Clinical Levels of Depression and Anxiety in Patients With Wet Age-Related Macular Degeneration

Senra

Balaskas

Mahmoodi

et al. 2017

American Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: To investigate detailed patient experiences specific to receiving vascular endothelial growth factor inhibitors (anti-VEGF) for wet Age-Related Macular Degeneration (wAMD), and to acquire a snapshot of the frequency of clinically significant levels of depression, anxiety and post-traumatic stress among patients and levels of burden in patients' carers. Design: Observational cross-sectional mixed-methods study Methods: 300 patients with wAMD receiving anti-VEGF treatment and 100 patient carers were recruited. Qualitative data on patients' experience of treatment were collected using a structured survey. Standardised validated questionnaires were used to quantify clinically significant levels of anxiety, depression, post-traumatic stress, as well as cognitive function and carers' burden. Results: Qualitative data showed that 56% of patients (n =132) reported anxiety related to anti-VEGF treatment. The main sources of anxiety were fear of going blind due to intravitreal injections, and concerns about treatment effectiveness rather than around pain. From validated questionnaires, 17% of patients (n=52) showed clinical levels of anxiety, and 12% (n=36) showed clinical levels of depression. Depression levels, but not anxiety, were significantly higher in patients who received up to 3 injections compared to patients who received from 4 to 12 injections (ANOVA P=.027) and compared to patients who received more than 12 injections (ANOVA P=.001). Conclusions: Anti-VEGF treatment is often experienced with some anxiety related to treatment regardless of the number of injections received. Clinical levels of depression seem to be more frequent in patients at early stages of anti-VEGF treatment. Strategies to improve patient experience of treatment and minimise morbidity are suggested.Key Words: Wet Age-Related Macular Degeneration; Anti-VEGF; Depression; Anxiety; Experience.Abstract (MUST be submitted as a separate file) 1

show abstract

Section: Discussioncontrasting

confidence: 91%

Experience of Anti-VEGF Treatment and Clinical Levels of Depression and Anxiety in Patients With Wet Age-Related Macular Degeneration

Senra

Balaskas

Mahmoodi

et al. 2017

American Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…However, in this study, the models were poorly adjusted without including socio-economic and behavioral factors or comorbidity, and only adjusting for chronic diseases as a single score. In a large cross-sectional nationally representative sample of US adults (Zhang et al, 2013) (23% of participants ≥ 65 years) visual function loss was also associated with depression after multiple adjustment but visual acuity was not. Impairment of optical organs may have effects on visual acuity but also on contrast sensitivity (Alexander et al, 1988) and visual field.…”

Section: Vision Loss As a Risk Factor For Depressive Symptomatologymentioning

confidence: 97%

A prospective study of the bi-directional association between vision loss and depression in the elderly

Carrière

Delcourt

Daïen

et al. 2013

Journal of Affective Disorders

View full text Add to dashboard Cite

show abstract

“…[17**] This study adds to an abundance of evidence that shows the salience of impaired function over degree of vision loss on quality of life and depression. [18] …”

Section: Introductionmentioning

confidence: 99%

Update on depression and age-related macular degeneration

Casten¹,

Rovner

2013

Current Opinion in Ophthalmology

Self Cite

View full text Add to dashboard Cite

Introduction This review updates the literature on depression in age-related macular degeneration. Purpose of review Treatment for AMD has been revolutionized since the 2004 review of depression and AMD. New data describing the prevalence of depression in AMD, as well as novel interventions for managing depression in AMD, are discussed. Recent findings Depression continues to be prevalent in AMD and new information is available on the pathways by which impaired vision leads to depression. Strategies for the treatment of depression in patients with impaired vision have evolved. Summary AMD is still a major risk factor for depression and people with activity restriction due to vision loss are at greatest risk. An integrated approach to depression management in older adults with impaired vision may be the best course of action.

show abstract

Association Between Depression and Functional Vision Loss in Persons 20 Years of Age or Older in the United States, NHANES 2005-2008

Cited by 212 publications

References 73 publications

Experience of Anti-VEGF Treatment and Clinical Levels of Depression and Anxiety in Patients With Wet Age-Related Macular Degeneration

Experience of Anti-VEGF Treatment and Clinical Levels of Depression and Anxiety in Patients With Wet Age-Related Macular Degeneration

A prospective study of the bi-directional association between vision loss and depression in the elderly

Update on depression and age-related macular degeneration

Contact Info

Product

Resources

About